The Journal of Rheumatology最新文献

{"title":"Multiple Hematoma, Purpura, and Ulcers in a Patient With Rheumatoid Arthritis.","authors":"Saeko Yamada,Takanori Azuma","doi":"10.3899/jrheum.2025-0516","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0516","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"730 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144763246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?","authors":"Stanley B Cohen,Kenneth G Saag","doi":"10.3899/jrheum.2025-0726","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0726","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144763249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Genetic Landscape of Psoriatic Arthritis: A Narrative Review of Recent Genomic Studies.","authors":"Hugues Allard-Chamard,Proton Rahman","doi":"10.3899/jrheum.2025-0273","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0273","url":null,"abstract":"The recent availability of large-scale genomic datasets in psoriatic disease, combined with advances in molecular tools, next-generation genomic technologies, and informatics, has led to a better understanding of the genomic basis of psoriatic arthritis (PsA). While no current genetic tests exist for the management of PsA, the potential for early diagnosis and treatment orientation through genomic studies remains a source of continued optimism. Ongoing studies aim to advance the stratification, prognosis, and pharmacogenomics of PsA. This review highlights recent advances in the genomics of PsA, focusing on genomic variants that may become clinically actionable. We will discuss the importance of elucidating family history, highlight potential clinically significant psoriatic genes, emphasize genetic variants that may identify PsA among patients with psoriasis, and explore the emerging roles of transcript profiling, single-cell sequencing, and spatial omics in PsA.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144763298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of a Nationwide Multicenter Study in Childhood Sjögren Disease.","authors":"Gülşah Kılbaş,Semra Ayduran,Seher Şener,Taner Coşkuner,Kadir Ulu,Hakan Kısaoğlu,Esma Aslan,Elif Kılıç Könte,Ceyda Arslanaoğlu,Tuncay Aydın,Yağmur Şadırvan Oğuzkaya,Figen Çakmak,Deniz Gezgin Yıldırım,Melike Mehveş Kaplan,Saadet Nilay Tiğrak,Serkan Türkuçar,Hafize Emine Sönmez,Miray Kışla Ekinci,Kübra Öztürk,Ferhat Demir,Esra Bağlan,Burcu Bozkaya,Sema Nur Taşkın,Selcan Demir,Erdal Sağ,Ezgi Deniz Batu,Sezgin Şahin,Sevcan A Bakkaloğlu Ezgü,Sara Sebnem Kılıc,Ayşenur Paç Kısaarslan,Banu Çelikel Acar,Mukaddes Kalyoncu,Nuray Aktay Ayaz,Betül Sözeri,Erbil Ünsal,Özgür Kasapçopur,Seza Özen,Selçuk Yüksel","doi":"10.3899/jrheum.2024-1048","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1048","url":null,"abstract":"OBJECTIVEThis nation-wide, multicenter study was conducted to assess the demographic, clinical features, treatment regimens, and prognosis of primary Sjögren disease (SjD) in childhood.METHODSThis retrospective study included a total of 81 patients under 18 years of age from 21 pediatric rheumatology centers. Among these, 51 patients fulfilled the diagnosis of childhood SjD strictly according to the 2016 ACR/EULAR classification criteria. The remaining 30 patients, who did not fully meet these criteria but exhibited clinical and laboratory findings suggestive of SjD, were categorized as 'at-risk for childhood SjD' to highlight diagnostic challenges and spectrum of early presentations, based on comprehensive clinical evaluation by experienced pediatric rheumatologists.RESULTSThe cohort consisted of 81 patients (85.2% female, 14.8% male) with a median age at symptom onset of 11.4 years and a median follow-up of 24 months. Common clinical manifestations included dry mouth, dry eyes, arthralgia, fatigue, and parotitis. Fifty-one of the 81 patients met the 2016 ACR/EULAR classification criteria, while the remaining 30 were classified as an at-risk group. The most common clinical findings in 30 patients 'at-risk group' were xerostomia (90%), arthralgia (56.7%), fatigue (50%), and dry eyes (43.3%). Dry mouth, and peripheral nervous system involvements were found to be higher in patients categorized as at-risk (p = 0.03, p = 0.02, respectively).CONCLUSIONThe current classification criteria for childhood SjD appear to be inadequate, highlighting the need for pediatric-specific criteria that more accurately reflect the distinct clinical patterns observed in children.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144640098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial use and serious infections among psoriatic arthritis patients after initiating tumor necrosis factor inhibitors: a nationwide matched cohort study.","authors":"Telma Thrastardottir,Aron Hjalti Bjornsson,Alexis Ogdie,Arna Hauksdottir,Sigurdur Yngvi Kristinsson,Bjorn Gudbjornsson,Thorvardur Jon Love, ","doi":"10.3899/jrheum.2025-0029","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0029","url":null,"abstract":"OBJECTIVETo analyse antimicrobial use and serious infections (SI) among psoriatic arthritis (PsA) patients before and after initiating TNF inhibitor (TNFi) treatment.METHODSIn this nationwide matched cohort study, we extracted data on PsA patients initiating TNFi from 2005 to 2018 from the ICEBIO registry and matched them by age, sex, and calendar time to five randomly selected comparators from the general population. All filled prescriptions for antimicrobials, glucocorticoids, and methotrexate two years before and after initiating TNFi treatment were extracted from the Icelandic Prescription Medicines Register. All infection-related hospitalisations, a proxy for SI, were extracted from the Icelandic Hospital Discharge Register.RESULTSThe study included 399 PsA patients and 1,986 matched comparators. Patients received more antimicrobial prescriptions before TNFi treatment, with a mean number of prescriptions (NP) per year of 1.26 vs. 0.60 (p<0.001). The mean NP increased to 1.64 (p<0.001) in the 12 months following TNFi initiation but returned to baseline thereafter. No statistically significant increase in SI was found. Adjusted for covariates, PsA patients had HR of 1.43 (95% CI 1.18-1.72, p<0.001) for receiving a prescription for antimicrobials following TNFi treatment initiation compared to themselves before TNFi treatment. The risk was increased in the first year after treatment initiation but not in the second year, suggesting a transient effect.CONCLUSIONFollowing TNFi initiation, antimicrobial use rose temporarily, with no significant increase in SI. These results support the safety of TNFi in PsA management and the risk of SI should not weigh heavily in treatment decisions.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"92 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144640100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalizing Management of Systemic Sclerosis-Associated Interstitial Lung Disease: Are Autoantibodies the Key for Risk Stratification?","authors":"Cosimo Bruni,Muriel Elhai,Oliver Distler","doi":"10.3899/jrheum.2025-0692","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0692","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144640101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Necrotizing and non-Necrotizing Granulomatous Reactions in Cancer Patients Treated with Immune Checkpoint Inhibitors: a Systematic Literature Review.","authors":"Elizabeth Y Wang,Genna Braverman,Nilasha Ghosh,Deanna P Jannat-Khah,Karmela K Chan,Jean-Marie Michot,Bridget Jivanelli,Anne R Bass","doi":"10.3899/jrheum.2025-0108","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0108","url":null,"abstract":"OBJECTIVEImmune checkpoint inhibitors (ICI) have improved cancer outcomes but often cause immune-related adverse events (irAE), including granulomatous reactions (GR). We analyzed GR in patients receiving anti-CTLA4, anti-PD1/PDL1 and combination anti-CTLA4/PD1 therapies.METHODSWe performed a literature review of GR in patients receiving ICI. Data were extracted from 166 articles, including demographics, GR organ distribution and pathological findings.RESULTSIn 261 patients, the mean age of GR onset was 59.3 ± 13.0 years. The most common cancer types were melanoma (57%) and lung cancer (21%). Lymph nodes (35%) and skin (24%) were the predominantly affected organs, however GR also involved the liver, kidney, and bone. Granulomas were non-necrotizing in 64% of cases and necrotizing in 15% of cases. Forty-five percent of patients were treated with systemic steroids, and eleven percent required a steroid-sparing agent. Median follow-up time was 10.1 [4, 22] months. Most GR (64%) had resolved by last follow-up. Compared to those treated with combination ICI, patients treated with anti-PD1/PDL-1 monotherapy were older and had a longer time to onset of the GR. They were less likely to be treated with steroids for GR. In melanoma patients, necrotizing GR were more common in combination ICI. GR in the lungs and nodes were more likely to be non-necrotizing, and GR in the liver were more commonly necrotizing.CONCLUSIONGR in cancer patients treated with ICI can occur in many organ systems and were most commonly non-necrotizing. Patients treated with combination ICI had more severe reactions. Most granulomatous reactions resolved with steroid treatment or ICI discontinuation.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"96 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144640099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpes Zoster Vaccine and Rheumatoid Arthritis.","authors":"Shih-Wei Lai","doi":"10.3899/jrheum.2025-0272","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0272","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144533523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual Disease Activity and Burden of Disease in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA).","authors":"Denis Choquette,Dafna D Gladman,Robert D Inman,Proton Rahman,Marie-Claude Laliberté,Pierre-André Fournier,Tanya Girard,Stephanie Wichuk,Louis Coupal,Vinod Chandran,Sherry Rohekar,Tristan Boyd,Michel Zummer,Nicolas Richard,Carter Thorne,Dianne Mosher,Olga Ziouzina,Alexander Tsoukas,Michael Starr,Jonathan Chan,Sibel Zehra Aydin,Walter P Maksymowych","doi":"10.3899/jrheum.2024-1303","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1303","url":null,"abstract":"OBJECTIVEThere is a key knowledge gap in quantifying residual disease activity in Canadian patients with axial spondyloarthritis (axSpA). The objective of this study was to evaluate and describe residual disease activity and burden of disease in Canadian patients with axSpA.METHODSThis was an observational, retrospective analysis of data extracted from the Rhumadata™ (Québec), SPondyloArthritis Research Consortium of Canada (SPARCC, East/Atlantic and West regions, and Ontario), and FOllow-up Research Cohort of Ankylosing SpondyliTis (FORCAST, Alberta) registries. The primary endpoint was proportion of patients who failed to achieve sustained low disease activity (LDA) at 12 months; LDA was defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score <3 and sustained LDA defined as achieving LDA at both 6 and 12 months after the most recent change in treatment. Analyses included outcomes by treatment class (nonsteroidal anti-inflammatory drugs [NSAIDs], tumor necrosis factor inhibitor, or interleukin-17 inhibitor).RESULTSA total of 980 patients (Rhumadata™, N=488; SPARCC, N=239; FORCAST, N=253) were included. Nearly half of patients with axSpA from Rhumadata™/Québec (49.5%) and FORCAST/Alberta (55.3%) and 65.8% of those from SPARCC/Ontario failed to achieve LDA (BASDAI <3) at 6 months after treatment initiation. At 12 months, failure to achieve sustained LDA rose to 62.0% in Rhumadata™/Québec, 65.1% in FORCAST/Alberta, and 81.0% in SPARCC/Ontario. Pain persisted in nearly half of all patients.CONCLUSIONThis analysis demonstrated that most Canadians with axSpA failed to achieve sustained LDA after 12 months of initiating their latest therapy and confirms a high unmet need for additional treatments.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144533519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial Cell and Neutrophil Activation in Untreated Intercritical Patients With Gout.","authors":"Michael Toprover,Binita Shah,Kamelia Drenkova,Ana Leonard,Michael H Pillinger,Michael Garshick","doi":"10.3899/jrheum.2025-0255","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0255","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"154 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144533613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}